Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Other Non-Current Assets (2016 - 2026)

Angiodynamics' Other Non-Current Assets history spans 16 years, with the latest figure at $10.5 million for Q1 2026.

  • For Q1 2026, Other Non-Current Assets rose 8.44% year-over-year to $10.5 million; the TTM value through Feb 2026 reached $10.5 million, up 8.44%, while the annual FY2025 figure was $10.4 million, 8.49% down from the prior year.
  • Other Non-Current Assets reached $10.5 million in Q1 2026 per ANGO's latest filing, down from $11.1 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $11.4 million in Q2 2024 to a low of $6.2 million in Q2 2023.
  • Average Other Non-Current Assets over 5 years is $10.2 million, with a median of $10.6 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: plummeted 41.84% in 2022, then skyrocketed 84.74% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $10.7 million in 2022, then fell by 12.05% to $9.4 million in 2023, then rose by 7.14% to $10.1 million in 2024, then rose by 9.6% to $11.1 million in 2025, then decreased by 5.19% to $10.5 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Other Non-Current Assets are $10.5 million (Q1 2026), $11.1 million (Q4 2025), and $9.5 million (Q3 2025).